Chemours (NYSE:CC) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Chemours (NYSE:CC) from a hold rating to a strong-buy rating in a research note published on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Chemours’ Q1 2027 earnings at $0.39 EPS, Q3 2027 earnings at $0.56 EPS, Q4 2027 earnings at $0.53 EPS, Q2 2028 earnings at $0.61 EPS and FY2028 earnings at $2.38 EPS.

A number of other equities research analysts also recently weighed in on the company. Alembic Global Advisors reissued an “overweight” rating and set a $30.00 target price on shares of Chemours in a research report on Wednesday, May 13th. UBS Group boosted their price target on Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, May 8th. JPMorgan Chase & Co. upped their price target on Chemours from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, May 21st. Weiss Ratings reiterated a “sell (d)” rating on shares of Chemours in a research report on Friday, July 17th. Finally, Morgan Stanley lifted their price objective on Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Chemours currently has a consensus rating of “Moderate Buy” and an average price target of $24.10.

Chemours Price Performance

NYSE:CC opened at $18.24 on Tuesday. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87. Chemours has a one year low of $10.44 and a one year high of $28.67. The company has a fifty day moving average price of $20.61 and a 200 day moving average price of $19.85. The stock has a market cap of $2.74 billion, a P/E ratio of -6.91 and a beta of 1.41.

Chemours (NYSE:CC) last posted its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.10. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The company had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the business posted $0.13 EPS. The business’s quarterly revenue was up 1.0% on a year-over-year basis. Analysts anticipate that Chemours will post 1.18 earnings per share for the current year.

Chemours Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were given a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 1.9%. The ex-dividend date was Friday, May 15th. Chemours’s payout ratio is -13.26%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CC. SG Americas Securities LLC increased its position in Chemours by 478.4% in the 4th quarter. SG Americas Securities LLC now owns 236,236 shares of the specialty chemicals company’s stock valued at $2,785,000 after acquiring an additional 195,393 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Chemours during the first quarter worth approximately $3,745,000. Vanguard Group Inc. lifted its position in shares of Chemours by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 17,920,868 shares of the specialty chemicals company’s stock worth $211,287,000 after purchasing an additional 490,778 shares in the last quarter. Versor Investments LP bought a new stake in shares of Chemours during the fourth quarter valued at approximately $314,000. Finally, Penn Capital Management Company LLC grew its stake in shares of Chemours by 113.0% during the fourth quarter. Penn Capital Management Company LLC now owns 1,386,819 shares of the specialty chemicals company’s stock valued at $16,366,000 after purchasing an additional 735,668 shares during the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

About Chemours

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.